Hyderabad-based pharmaceutical company Dr. Reddy’s Laboratories (DRL) has launched Obeda, a generic version of semaglutide, in India for the management of Type 2 diabetes. The move comes as demand for glucagon-like peptide-1 (GLP-1) agonists rises in the country, driven by increasing rates of diabetes and obesity. The launch of Obeda aims to significantly lower the cost of treatment, offering a more affordable option for patients compared to the branded drug Ozempic, marketed by Novo Nordisk.
Obeda is priced at ₹4,200 per month for the 2mg and 4mg dosages, representing a 62% reduction from the highest dosage of Ozempic, according to DRL. This price difference is particularly significant in India, where over 101 million people live with diabetes, and another 136 million are prediabetic, making it a key market for GLP-1 therapies. The increasing prevalence of type 2 diabetes in India, second only to China, coupled with rising obesity rates, has fueled the demand for effective treatments like semaglutide.
Semaglutide’s Patent Expiration and Market Impact
The launch of Obeda follows the recent expiration of semaglutide’s patent protection, opening the door for generic manufacturers to enter the market. GLP-1 agonists work by regulating blood sugar, increasing feelings of fullness, and slowing down stomach emptying, leading to improved glucose control and potential weight loss. The Indian pharmaceutical market is already responding to this change, with sales of injectable GLP-1 agonists, including tirzepatide and semaglutide, increasing by 177% in the last year, rising from ₹571 crore in February 2025 to ₹1,446 crore in February 2026, according to industry data.
DRL anticipates a surge in competition, with over 50 generic versions of semaglutide expected to become available in India within the next month. The company plans to sell 12 million injectable semaglutide pens in the first year of launch, aiming to become a top five player in the Indian semaglutide market, as stated by M V Ramana, CEO of Branded Markets (India & Emerging Markets) at a press conference.
Expanding Beyond Diabetes: Weight Management and Global Ambitions
Although initially approved for Type 2 diabetes management, DRL is also seeking regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to market a generic version of semaglutide for weight management. This expansion reflects the growing recognition of semaglutide’s efficacy in addressing obesity, a significant health concern in India and globally.
DRL’s ambitions extend beyond the Indian market. The company is committed to a “One Product, One Quality” approach, aiming to introduce generic semaglutide in several countries. However, the launch in Canada has been temporarily paused due to a Notice of Non-Compliance (NON) from Health Canada regarding its Abbreviated New Drug Submission (ANDS). “We are in constant touch with the Canadian regulators and have sent our replies to their queries,” Ramana confirmed.
Strategic Partnerships and Supply Chain Control
To broaden its reach, DRL plans to partner with two other drug manufacturers to produce Obeda under their respective brand names. The company is also in discussions with global players for potential overseas market collaborations. DRL emphasized its control over the supply chain, stating that both the active pharmaceutical ingredient (API) development and formulation are conducted entirely in-house. This vertical integration is intended to ensure consistent quality and reliable supply of Obeda.
DRL CEO Erez Israeli highlighted the significance of this launch, stating, “Here’s one launch out of many we are going to have this year from the GLP-1 receptor agonists therapy space.” The company’s commitment to expanding its portfolio in this therapeutic area underscores the growing importance of GLP-1 agonists in addressing metabolic diseases.
The Rise of GLP-1 Agonists in India
The increasing demand for GLP-1 agonists in India is driven by a confluence of factors, including a rising diabetes prevalence, increasing awareness of the benefits of these medications, and a growing focus on weight management. The World Health Organization (WHO) estimates that India has the second-highest population living with type 2 diabetes after China. The affordability of generic options like Obeda is expected to further increase access to these life-changing medications.
The launch of Obeda represents a significant step towards making semaglutide more accessible to patients in India. As more generic versions enter the market, competition is expected to drive down prices further, benefiting individuals struggling with Type 2 diabetes and obesity. The coming months will be crucial as DRL navigates regulatory approvals for weight management applications and expands its global footprint.
Disclaimer: The information provided in this article is for general informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
DRL will provide updates on its regulatory approvals and market expansion plans in the coming months. Readers are encouraged to share their thoughts and experiences with GLP-1 agonists in the comments below.
